Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 master protocol platform study of LY4395089-based intervention versus mirikizumab in adults with ulcerative colitis or Crohn's disease
MOH_2026-05-08_015811Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis and Crohn's disease comparing mirikizumab with LY4395089 + mirikizumab (2 arms). Primary endpoints: Ulcerative colitis endoscopic improvement at Week 12 and Crohn's disease endoscopic response at Week 12. Started Apr 2026; status: recruiting.
02
Drugs
LY4395089mirikizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2026-05-08_015811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-08_015811.